Induction of immunodeficiency in mice by injection with syngeneic splenocytes immune to semi-allogeneic hybrid cells. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Induction of immunodeficiency in mice by injection with syngeneic splenocytes immune to semi-allogeneic hybrid cells.

Cell Immunol. 1984 Oct 1;88(1):222-7. Unique Identifier : AIDSLINE MED/85002053
Kim BS

Abstract: Intravenous transfer of BALB/c spleen cells (1-10 X 10(6] immunized against semi-allogeneic hybrid cells bearing H-2k antigens into BALB/c mice resulted in splenomegaly (2- to 6-fold). As few as 2 X 10(4) spleen cells could transfer splenomegaly. A significant spleen enlargement was seen from 2 weeks after cell transfer and reached the peak level at 3 weeks. Those mice with splenomegaly displayed markedly reduced levels of proliferative responses to concanavalin A and lipopolysaccharide. However, the levels of the major Ig classes (i.e., IgG, IgM, and IgA) in the immunodeficient mice were significantly elevated. Such induction of immunodeficiency in mice may help further to understand the acquired immunodeficiency syndrome of humans.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Animal Disease Models, Animal H-2 Antigens/*IMMUNOLOGY Immunoglobulins/BIOSYNTHESIS Immunologic Deficiency Syndromes/*IMMUNOLOGY Lymphocyte Transformation Mice Mitogens/PHARMACOLOGY Spleen/IMMUNOLOGY Splenomegaly Time Factors JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDimmunologyanimaldiseasemodels,animalh-2antigens/KWDimmunologyimmunoglobulins/biosynthesisimmunologicdeficiencysyndromes/KWDimmunologylymphocytetransformationmicemitogens/pharmacologyspleen/immunologysplenomegalytimefactorsjournalarticle
850130
M8510089

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .